Reducing the carbon footprint of inhalers

Paul Hardman, managing consultant, Broughton, explores the current situation and ways of reducing greenhouse gases in this sector.  

Pressurised metered-dose inhalers (pMDIs) are essential for treating respiratory conditions like asthma and COPD, but their hydrofluorocarbon (HFC) propellants are potent greenhouse gases that contribute to global warming. As environmental concerns grow, reducing these emissions has become a priority in healthcare. The pharmaceutical industry can address these challenges by investing in research for low-global warming potential (low-GWP)…